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Abstract
Background: Coccidiosis is a major global veterinary health problem in intensively reared chickens. It is caused by
apicomplexan parasites of the genus Eimeria.
Principal Findings: A subunit vaccine composed of purified antigens from the gametocytes of Eimeria maxima was used to
stimulate the production and transfer of maternal antibodies between breeding hens and their hatchlings. The vaccine was
injected into hens twice before they began laying eggs. Immunization had no adverse affects on egg laying or health of the
hens and resulted in high antibody levels throughout the life of the hens. Progeny of immunized hens excreted significantly
less oocysts of various species of Eimeria in their faeces than chicks from unvaccinated hens. Furthermore, the offspring of
vaccinated hens developed stronger natural immunity to Eimeria, so that they were resistant to challenge infection even at
8 weeks of age, well after all maternal antibodies had left their circulation. Field trials were conducted in South Africa, Brazil
and Thailand, involving at least 1 million progeny of vaccinated hens and at least 1 million positive control birds (raised on
feed containing anticoccidial drugs or immunized with a live vaccine) in each country. Additionally, trials were carried out in
Israel involving 60 million progeny of vaccinated hens and 112 million positive control birds. There were no significant
differences in growth rate, feed conversion ratios or mortality in the offspring of vaccinated hens compared with the
positive control chickens in any of these countries regardless of different management practices, different breeds of
chickens or climate.
Conclusions: These results demonstrate that a vaccine composed of antigens purified from the gametocytes of Eimeria can
be used safely and effectively to prevent the deleterious effects of coccidiosis. It is the first subunit vaccine against any
protozoan parasite to be successfully applied on a commercial scale.
Citation: Wallach MG, Ashash U, Michael A, Smith NC (2008) Field Application of a Subunit Vaccine against an Enteric Protozoan Disease. PLoS ONE 3(12): e3948.
doi:10.1371/journal.pone.0003948
Editor: Adam J. Ratner, Columbia University, United States of America
Received August 19, 2008; Accepted November 8, 2008; Published December 16, 2008
Copyright:  2008 Wallach et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work received support from ABIC Ltd, Israel, and the Australian Research Council Linkage Grant Scheme (Project No. LP0454145). The trials
described in this manuscript were performed by independent research groups or poultry farmers who collected and analysed the data by themselves. The
decision to publish, interpretation of the data and preparation of the manuscript was carried out by Professor Michael Wallach and Associate Professor Nick Smith
who had no role in funding the project.
Competing Interests: MGW and NCS receive research funding from ABIC Ltd and UA and AM are employees of ABIC Ltd, an Israeli company that markets a
vaccine, CoxAbicH, which is composed of the Eimeria maxima gametocyte antigens described in this paper.
* E-mail: michael.wallach@uts.edu.au
Introduction
Coccidiosis is a major global veterinary health problem
impacting on the production of domesticated sheep, cattle, poultry
and even fish. It is a particularly problematic disease in chickens
(due to their intense rearing conditions), costing the industry £38
million per year in the UK alone and, extrapolating from this, over
2 billion US dollars to the world’s farmers and poultry industries
annually [1]. It is caused by various species of the genus, Eimeria,
which are ubiquitous parasites of the Phylum Apicomplexa. In
chickens, there are several species that cause the disease, the three
most important being Eimeria tenella, Eimeria maxima and Eimeria
acervulina. Infection with Eimeria begins with the ingestion of
sporulated oocysts, which are found in the floor litter of any typical
poultry house. Sporozoites are liberated from the oocysts and
rapidly invade the host intestinal epithelium, commencing the first
of several asexual rounds of reproduction that rapidly amplify the
number of parasites infecting individual birds. Ultimately, the
asexual parasites (merozoites) develop into macro- and microga-
metocytes, the latter fertilising the former to produce oocysts,
which are shed in the faeces of chickens, contaminating the
environment of whole flocks of birds. For each oocyst ingested by a
naive chicken, several hundred thousand new oocysts are
produced. The oocyst possesses an extremely hardy protective
wall – the oocyst wall – that protects the parasites contained within
it and facilitates their successful transmission from one host to the
next [2]. The oocyst wall originates from the fusion of specialized
organelles – the wall forming bodies – found in the macrogametes
of the parasite [3]. We have previously provided evidence that
proteins within these organelles are processed and cross-linked via
dityrosine bonds to form the essential structure of the oocyst wall
[4]. Two of the key proteins of this process are gam56 and gam82,
the main components of a vaccine comprised of antigens from the
gametocytes of Eimeria maxima [4–6]. It is believed that antibodies
stimulated by vaccination interfere with the formation of cross-
links between these proteins and, hence, inhibit oocyst wall
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formation, effectively interrupting the parasite’s lifecycle at the
transmission stage [2,4–6].
We [4–7] and others [8–10] have previously shown that
immunization of breeding hens – either with purified gametocyte
antigens or via deliberate infection with E. maxima – results in the
passive maternal transfer of large quantities of anti-parasite IgG from
hen to egg yolk and, hence, to young chicks, protecting those chicks
against infection. In laboratory-controlled conditions, the level of
protection is very high, with complete abrogation of oocyst shedding
being observable [5–7]. This maternal immunity is able to give
protection against multiple species of Eimera [11], unlike direct
immunity, which is species-specific [12,13]. Furthermore, in floor
pen trials designed to mimic field conditions, chicks originating from
vaccinated hens shed 60–70% fewer oocysts over their lifetime than
did chicks from unvaccinated hens [14]. This resistance to infection
outlasts the life of maternal antibodies in the growing birds and is
presumed to be a result of the fact that maternal immunity induced
by vaccination reduces, without totally eliminating, transmission of
oocysts between birds, allowing individual birds to develop their own
natural, anti-asexual stage immunity on top of the maternal
immunity arising from vaccination with gametocyte antigens.
(Anti-asexual stage immunity to Eimeria has long been recognised
to be extremely strong and effective and is the basis for the success of
attenuated live vaccines against coccidiosis [12,13,15]). This
explanation for the effectiveness of maternal immunization with
purified gametocyte antigens has never been tested formally.
Furthermore, to date, the commercial performance (ie weight gain,
feed conversion, survival) of the progeny of vaccinated hens has not
been reported. Thus, in the experiments reported here, we examined
the effect of vaccination with purified gametocyte proteins on (i) the
health and egg production of breeding hens, (ii) antibody levels in
commercial breeding hens, (iii) reduction of parasite reproduction in
the offspring of vaccinated hens at a variety of times after hatching,
and (iv) weight loss, feed conversion rate and mortality caused by
challenge infection with several species of Eimeria.
Results and Discussion
Safety and immunogenicity of vaccination with purified
gametocyte antigens in breeding hens
We evaluated the performance of breeder hens (Cobb, Ross,
ANAK and others) vaccinated with purified gametocyte antigens
in broiler breeder farms around the world. Breeding hens were
vaccinated twice prior to the start of their laying period (ie, at 15
and 20 weeks of age). We tested the null hypotheses that
immunization with purified gametocyte antigens has no deleteri-
ous effects on hen mortality or egg production. The hens suffered
no adverse reactions, no damage at the site of injection, and no
impairment of performance as a result of vaccination with purified
gametocyte antigens. Furthermore, in every farm where these
trials were conducted, the survival rate and the number of eggs
laid was not significantly different for vaccinated versus unvacci-
nated, control hens (Table 1). Thus, we must accept the null
hypothesis that immunization does not have any adverse affects on
maternal health or egg production. Indeed, on several farms there
actually appeared to be a slight (albeit not statistically significant),
unanticipated improvement in the performance of breeding flocks
that were vaccinated. Furthermore, the total number of chicks
hatched per hen was improved. In, for example, the Argentine
trial 119 eggs hatched in the vaccinated group vs. 116 in the
control group, for a total of 13,473 extra live chicks from the 4,646
vaccinated hens versus the 4,669 unvaccinated hens.
Hens were bled and ELISA carried out at various time points
post-vaccination. The commercial ELISA kit contains 96-well
plates coated with affinity purified gametocyte antigens, as well as
positive and negative control sera. The ELISA test results are
recorded as an S/P ratio, calculated as follows: (Sample optical
density value – Negative control optical density value)/(Positive
control optical density value – Negative control optical density
value). A cut-off S/P value of 0.4 has been determined by the
manufacturers (ABIC Ltd, Israel) to indicate a sufficiently high
antibody level to confer protective maternal immunity against
coccidiosis and is used as a key parameter in the quality control of
the commercial ELISA kit. As an example of our typical results,
ten breeder flocks from various countries (six from Israel, two from
South Africa, and one each from Argentina and Thailand) were
monitored throughout their entire laying period (Figure 1). In
these immunized flocks, the average ELISA S/P ratio was 0.8 or
higher for the first 3 months post-immunization, dropped to 0.6 at
4 months and remained well above the ELISA kit cut-off S/P ratio
of 0.4 throughout the hens’ laying period. In contrast, control
flocks had S/P values of less than 0.4 (0.1860.1, average6S.D.)
throughout the laying period of the hens’ life, most often in the
0.1–0.2 range. We believe that the maintenance of the high
specific IgG antibody levels in the vaccinated flocks is due to the
boosting effect of oocysts that are naturally encountered in every
chicken house worldwide. It is conceivable that, on some farms,
natural exposure by itself can lead to increased maternal antibody
levels, however, without vaccination, these natural titres are likely
to be variable, unreliable and relatively non-specific.
In summary, these field trials on breeding hens demonstrate the
long-term safety and immunogenicity of vaccination with purified
gametocyte antigens from E. maxima. The antibody levels
maintained in vaccinated flocks are sufficient to ensure the
transmission of protective antibodies to offspring throughout the
egg laying lifetime of the hens.
Table 1. The effect of vaccination with purified gametocyte
antigens of Eimeria maxima on mortality and egg production
by breeding hens.
Country
Number
of hens
Mortality
(%)
Eggs laid
per hen
Argentina (Cobb Breed)
Purified gametocyte antigen 4,646 9.08% 152
Control 4,669 17.41% 149
Brasil (Cobb Breed)
Purified gametocyte antigen Farm 1 19,854 15.58% 177
Control Farm 1 19,455 17.82% 177
Purified gametocyte antigen Farm 2 20,100 11.21% 176
Control Farm 2 20,218 14.96% 170
Purified gametocyte antigen Farm 3 18,747 4.09% 192
Control Farm 3 18,734 4.14% 188
Purified gametocyte antigen Farm 4 20,284 9.93% 180
Control 4 19,194 13.14% 178
India (Ross Breed)
Purified gametocyte antigen 3,500 7.9% 182
Control 3,500 10.4% 175
Breeding hens were injected intramuscularly with 50 mg of purified gametocyte
antigens emulsified in 0.5 ml of water-in-oil adjuvant at 15 and 20 weeks of age.
Mortality rates and egg production of the flocks of hens were monitored until
the end of their productive lives (around 60–65 weeks of age). Neither mortality
or egg production were affected by vaccination (one-way ANOVA).
doi:10.1371/journal.pone.0003948.t001
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Resistance to coccidiosis and the development of natural
immunity by the progeny of hens vaccinated with
purified gametocyte antigens
Commercial broiler breeder hens were vaccinated twice (at 15 and
20 weeks of age) with purified gametocyte antigens and eggs were
collected from 43 week old hens and incubated to hatching. At
different time points, the hatchlings were moved into clean cages and
challenged with various doses of E. tenella oocysts, depending on the
age of the hatchlings. Peak and total oocyst excretion, assessed by
daily faecal oocyst counts, was used to determine resistance to
infection induced by vaccination (see Table 2).
Unchallenged, 4 day old control chicks shed no detectable
oocysts, as expected. Peak oocyst excretion by chicks from
Figure 1. Effect of immunization with purified gametocyte antigens of Eimeria maxima on gametocyte antigen-specific antibody
levels in flocks of breeding hens. Commercial broiler breeder hens were vaccinated twice with purified gametocyte antigens (PGA) at 15 and 20
weeks of age. Sera (10–15 samples per flock) were collected at each time point post vaccination from 10 flocks of chickens (six from Israel, two from
South Africa, and one each from Argentina and Thailand). The ELISA results are expressed as an S/P ratio, which is calculated as follows: (Sample
optical density value – Negative control optical density value)/(Positive control optical density value – Negative control optical density value). Results
show the average S/P6Standard Error for the ten flocks at different times post-vaccination. The average S/P for four control flocks from some of the
same farms that were tested during the testing period are also shown.
doi:10.1371/journal.pone.0003948.g001
Table 2. The effect of maternal immunization with purified gametocyte antigens of Eimeria maxima on the development of
resistance to Eimeria tenella in offspring chickens.
Age of
challenge
Peak numbers of
oocysts per gram
faeces for vaccine birds
(average6S.D.)61023
(n =4 groups of 15
birds)
Peak numbers of
oocysts per gram
faeces for control birds
(average6S.D.)61023
(n =4 groups of 15
birds)
Peak %
reduction
in oocyst
excretion
by vaccine
birds
Overall numbers of
oocysts per gram
faeces, days 4–14
post-challenge, for
vaccinated birds
(average6S.D.)61023
(n =4 groups of 15
birds)
Overall numbers of
oocysts per gram
faeces, days 4–14
post-challenge,
for control birds
(average6S.D.)61023
(n =4 groups of 15
birds)
Overall %
reduction
in oocyst
excretion
by vaccine
birds
4 days 56.262.2 175.0681.7 67.9 115.065.5 310.9653.0 63.0
39 days 48.0636.9 405.76214.8 88.2 104.4692.9 713.66322.8 85.4
57 days 0.160.1 3.661.8 98.0 0.160.1 6.263.6 98.4
Commercial broiler breeder hens (14,532 vaccinated with purified gametocyte antigens and 7,256 control) were vaccinated twice with purified gametocyte antigens, (at
15 and 20 weeks of age). Eggs were collected from groups of vaccinated and unvaccinated 43-week old hens and incubated to hatching. At 4 days of age, four groups
of 15 male chicks from vaccinated and unvaccinated hens were challenged with 50 oocysts of E. tenella. At 39 and 57 days of age four groups of 15 chicks from each of
vaccinated and unvaccinated hens were challenged with 25,000 oocysts of E. tenella. Faeces were collected from days 4–14 after challenge infection and oocyst counts
performed. Oocyst excretion is expressed in two ways: [i] by peak oocyst excretion, which is a measure of the highest number of oocysts per gram of faeces on a single
day after challenge infection (generally day 7 post-challenge) for groups of 15 chickens; and [ii] overall oocyst excretion, which is a measure of the number of oocysts
per gram faeces found in the total faecal collection for days 4 to 14 post-challenge for groups of 15 chickens. The differences for both the peak and total oocyst counts
in the vaccinated and control groups at the three time points are all statistically significant at the p,0.05 level (one-way ANOVA, Student’s t-test).
doi:10.1371/journal.pone.0003948.t002
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gametocyte antigen vaccinated hens was reduced by 67.9%
compared with oocyst excretion by chicks from unvaccinated
hens (significant at p,0.05, Student’s t-test; Table 2), which is
similar to our previous results in laboratory-based trials [5,6,7,11].
A similar reduction was found in the comparison of total oocyst
counts, where we observed a 63% reduction in the progeny of
vaccinated hens (significant at p,0.05, Student’s t-test; Table 2).
At 39 days of age, peak oocyst excretion by birds from purified
gametocyte antigen vaccinated hens was reduced by 88.2%
compared with oocyst excretion by chicks from unvaccinated hens
(significant at p,0.05, Student’s t-test; Table 2). The same type of
experiment was conducted when the birds were 57 days old and, in
this experiment, peak oocyst excretion by chickens from the
vaccinated group was reduced by 98.0% (significant at p,0.05,
Student’s t-test; Table 2). Similar results were found in comparing
total oocyst counts, where we found a 85.4% and 98.4% reduction
at 39 days and 57 days of age, respectively (significant at p,0.05,
Student’s t-test; Table 2).
To sum up, we have shown that, not only does vaccination with
purified gametocyte antigens confer protection against Eimeria
species in the early life of chicks via maternal transfer of
antibodies, it also facilitates the development of active immunity
in older birds at 8 weeks of age. This is a significant milestone
because meat birds (broilers) typically live for only 5–7 weeks
before being slaughtered for market.
Growth and performance of the progeny of hens
vaccinated with purified gametocyte antigens
Weight gain is the most important performance parameter for a
chicken meat farmer and coccidiosis is recognised as one of the
major causes of weight loss in broilers. To test the effect of
maternal immunization with purified gametocyte antigens on
growth of broiler chickens, we raised groups of 100 broilers of the
Ross breed on litter that was deliberately seeded with oocysts of E.
maxima, E. tenella, E. acervulina and E. mitis (see Figure 2). We chose
this approach as a prelude to larger scale field trials because we
can control the level of seeding of the litter to guarantee an
exposure level that will have an affect on weight gain, whilst
otherwise mimicking commercial conditions. We were also able
to include negative control groups of chickens in these experi-
ments, which was not possible for the large-scale field trials (see
below).
At 34 days of age (ie, 24 days after exposure), the progeny of
unvaccinated hens raised on litter weighed more than 200 grams
less than either the progeny of vaccinated hens or the non-exposed
birds, that is, an effective weight loss of more than 20% as a result
of exposure to the four species of Eimeria (significant at p,0.0001,
one-way ANOVA; Figure 2). The hatchlings from vaccinated hens
were slightly, though not statistically significantly, heavier than the
non-exposed birds, confirming that maternal immunization with
Figure 2. Effect of maternal immunization with purified gametocyte antigens of Eimeria maxima on weight loss due to infection with
multiple species of Eimeria in progeny chickens. Commercial broiler breeder hens (14,532 vaccinated with purified gametocyte antigens and
7,256 control) were vaccinated twice with purified gametocyte antigens, (at 15 and 20 weeks of age). Eggs were collected from groups of vaccinated
and unvaccinated 43 week old hens and incubated to hatching. Three different groups of 100 broiler chickens were raised: (A) chicks from
unvaccinated hens, the chicks being raised in wire cages, with care being taken that they were not exposed to coccidian oocysts (i.e. non-exposed
control group); (B) chicks from unvaccinated hens, the chicks being raised under normal commercial conditions on floor litter that was seeded with
Eimeria oocysts; and (C) chicks from hens vaccinated twice with purified gametocyte antigens (CoxAbic), the chicks being raised under normal
commercial conditions on floor litter that was seeded with Eimeria oocysts. When the birds were 10 days old, eight out of one hundred birds were
orally infected with a cocktail containing 50 oocysts from each of four species of Eimeria – E. maxima, E. tenella, E. acervulina and E. mitis. Weekly
checking of the litter for oocysts confirmed that the infections were successful in all groups of birds, with peaks of between 300,000 and 459,000
oocysts being found in every gram of floor litter. At 34 days of age, the birds were weighed. Results are means6S.E. Group B chicken weight was
significantly lower than both Groups A and C (p,0.0001, one-way ANOVA, Student’s t-test), which were not significantly different from each other.
doi:10.1371/journal.pone.0003948.g002
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purified gametocyte antigens protects broilers against one of the
most serious effects of coccidiosis, namely, weight loss.
At 34 days of age, chickens were challenged by infecting individual
birds with high doses of oocysts of one of the following species of
Eimeria: E. maxima, E. tenella, E. acervulina or E. mitis (see Table 3).
Oocyst counts were performed on faeces collected from individual
birds on days 4–14 post infection and the birds were weighed 2 weeks
after infection (i.e. at 49 days of age). As expected, birds from
vaccinated and unvaccinated hens raised on floor litter (and,
therefore, exposed to coccidial infection which induces active
immunity) excreted greatly reduced numbers of oocysts of all species
compared with the birds raised coccidia-free in wire cages – in both
of these exposed groups of birds, whether challenged with E. maxima,
E. tenella, E. acervulina or E. mitis, oocyst excretion was at least 97% less
than that seen in naı¨ve birds (data not shown).
Infection with the various coccidia caused significant weight loss in
the cage-reared, previously unexposed birds, varying from 7% in the
case of E. tenella to 13% for E. acervulina, to 19% for E. maxima and
15% for E. mitis as compared to the unchallenged control group
(significant at p,0.05, one-way ANOVA; Table 3). In contrast, the
broilers from vaccinated hens that were floor-reared and previously
exposed to Eimeria species, lost only between 0.5–8.6% of their
weight (statistically these differences were not significant from the
unchallenged group of progeny of vaccinated hens) as a result of
challenge infection (Table 3). Broilers from unvaccinated hens that
were previously exposed to Eimeria in the floor litter, did not show a
significant loss of weight due to challenge, however, these broilers
went through an infection during the seeding phase, immunizing
them against reinfection. In addition, this unvaccinated, exposed
group started out more than 200 grams lighter than their gametocyte
antigen vaccinated counterparts and ended between 500 and 600
grams lighter (i.e. there was no weight compensation after the initial
effect of the seeding with Eimeria oocysts in the control group). Thus,
as a result of combined passive and active immunization, at 49 days
of age the progeny of purified gametocyte antigen vaccinated hens
were substantially heavier than both the cage-reared and floor-
reared broilers from unvaccinated hens.
Our results showing protection against weight gain in small-
scale floor-pen trials, led to large-scale field trials that were
conducted on commercial farms in Brazil, Thailand, Israel and
South Africa. As it is not possible to ask poultry farmers to
compromise their profit margins by raising large numbers of
broilers without any protection against coccidiosis, our large-scale
field tests of the gametocyte antigen vaccine were evaluated
against a ‘‘gold standard’’ positive control, either anti-coccidial
drug incorporated into the feed of the broilers or a known,
effective live vaccine regimen. Thus, our null hypothesis was that
the growth and survival rates of offspring of hens vaccinated with
purified gametocyte antigens are no less than the ‘‘gold standard’’
positive control chickens
The trials involved at least 1 million progeny of vaccinated hens
and at least 1 million positive control birds in each country,
allowing us to do a robust assessment of performance of these
broiler chickens on four continents, with distinct climates and also
different rearing conditions (eg, in Israel and South Africa, litter is
always cleaned out between each flock, whereas in Brazil litter is
occasionally reused). The trials that were carried out in Israel were
particularly extensive, involving 60 million progeny of vaccinated
hens and 112 million positive control birds.
Table 4 summarises the results in terms of country, age of
slaughter, weight, feed conversion ratio (FCR = kg feed con-
sumed/net weight gain; the lower the FCR the better), mortality
and the EU performance index. The EU index was calculated
using the following formula: (Body weight (g)610)/(FCR6slaugh-
ter age in days) and gives a powerful measure of overall flock
performance and profitability (the higher the EU index the better).
In all trials, in all countries, the performance of offspring broilers
from gametocyte antigen vaccinated hens was not significantly
different to that of medicated or live vaccine control groups; this is
true for all aspects of broiler growth. Thus, we must accept the null
hypothesis that the growth and survival rates of progeny from hens
vaccinated are the same as those of positive control chickens.
Indeed, though the differences are not statistically different, in all
but two trials (Fram B, Brazil and Farm A, Thailand) the EU
Index was slightly higher in the progeny of vaccinated hens.
Outcomes and General Conclusions
In the present study, involving 180 million broiler chickens, we
have demonstrated the effectiveness of the first antiparasitic
subunit vaccine of any kind used on a commercial scale worldwide.
Table 3. The effect of maternal immunization with purified gametocyte antigens of Eimeria maxima and natural immunity
induced by exposure to oocysts on weight loss caused by various species of Eimeria in offspring chickens.
Challenge
Species
A. Broilers from unvaccinated hens raised
coccidia free (ie, in wire cages)
B. Broilers from unvaccinated hens
raised with exposure to coccidia (ie,
in floor litter)
C. Broilers from purified gametocyte
antigen vaccinated hens, raised with
exposure to coccidia (ie, on floor litter)
Average
Weight6S.D. (g)
% Weight loss vs.
unchallenged,
unexposed broilers
Average Weight
(g)
% Weight loss vs.
unchallenged,
unexposed broilers
Average
Weight6S.D. (g)
% Weight loss vs.
unchallenged,
unexposed broilers
Unchallenged 23466157 - 17916367 23.6 23556279 -
E. tenella 21766210 7.2* 18696214 20.3 23436172 0.5
E. acervulina 20466206 12.8* 18616174 20.7 22316245 5.3
E. maxima 19106250 18.6* 18336316 21.9 21516175 8.6
E. mitis 19926188 15.1* 17956312 23.5 21896313 7.0
Commercial broiler breeder hens were vaccinated and their offspring raised as described in the legend to Figure 2. At 34 days of age, the birds were divided into
fourteen cages each containing five birds. The chickens were challenged by infecting individual birds with oocysts of one of the following species of Eimeria: E. maxima
(25,000 oocysts), E. tenella (25,000 oocysts), E. acervulina (80,000 oocysts) or E. mitis (120,000 oocysts) with three replicates of five chickens per species. Two replicates of
five chickens were left unchallenged (sham dosed with sterile water). The birds were weighed 2 weeks after infection. In Group A, challenge infection with every species
of Eimeria caused a significant loss of weight versus unchallenged chickens (* p,0.05; one-way ANOVA, Student’s t-test). There was no significant weight loss in
challenged birds in Group B or Group C versus unchallenged birds.
doi:10.1371/journal.pone.0003948.t003
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This vaccine contains antigens purified in native form from the
gametocytes of E. maxima. It induces the production of high levels of
protective IgG antibodies that are transferred from hens to egg yolks
and, thence, to offspring broiler chickens. As a result of this maternal
immunity, chickens can be raised without the need for any in-feed
anti-coccidial drugs. This vaccination strategy reduces transmission
between birds or, in other words, controls the level of overall
infection in any given flock of chickens rather than preventing
infection of individual birds, per se. It achieves this by stimulating
production of antibodies that target proteins destined to be processed
and cross-linked to form the oocyst wall of the parasite, a structure
that is absolutely essential for the survival of the parasites outside of
their host and, therefore, vital for transmission of parasites from host
to host [2]. Importantly, because of the conserved, functional
importance of oocyst wall formation in the parasites’ lifecycle,
immunization with the gametocyte antigens confers protection
against a range of coccidial parasites even though it is composed of
antigens from the gametocytes of E. maxima only. Another major
benefit of this transmission-blocking immunity is that, in addition to
the protection conferred by the maternal transfer of the IgG
antibodies, individual chickens are additionally able to develop their
own strong, natural immunity to the asexual stages of the parasite,
which protects them in later weeks, well after maternal antibody
levels have waned.
Materials and Methods
Production of purified gametocyte antigens
Purified gametocyte antigens were produced by ABIC Ltd, Bet
Shemesh, Israel as described previously [6], and according to the
manufacturer’s standard operating procedures, from the highly
enriched gametocyte stages of Eimeria maxima.
Vaccination with purified gametocyte antigens
Affinity purified gametocyte antigens were emulsified in a
water-in-oil emulsion and tested for sterility, stability and safety.
Table 4. The effect of maternal immunization with purified gametocyte antigens of Eimeria maxima on the growth performance
of progeny broiler chickens raised under commercial conditions on farms in Brazil, Thailand, Israel and South Africa.
Country Group Number of Chickens Age at Slaughter Mortality (%) FCR Final Weight (g) EU Index
Brazil
Farm A
PGA 17,000 49 5.88% 2.090 2,810 259
Drug 17,000 49 5.84% 2.180 2,680 237
Farm B
PGA 23,200 48 3.84% 1.770 2,720 311
Drug 23,200 48 3.00% 1.810 2,790 315
Farm C*
PGA 1,300,000 46 4.48% 2.020 2,296 235
Live vaccine 1,250,000 46 5.10% 2.020 2,296 233
Thailand
Farm A*
PGA 1,205,760 44 2.40% 1.830 2.345 291
Drug 3,259,017 44 2.75% 1.790 2.375 301
Farm B
PGA 346,800 45 2.30% 2.485 1.83 300
Drug 225,600 45 2.50% 2.485 1.83 295
Israel**
PGA 60,000,000 45 5.48% 2.000 2.110 237
Drug 112,000,000 45 5.73% 2.005 2.148 234
South Africa
PGA 755,000 38 4.33% 1.836 1.790 257
Drug 795,000 38 4.42% 1.843 1.784 255
PGA 137,280 38 3.60% 1.720 2.000 292
Live vaccine 126,720 38 4.41% 1.760 1.970 281
PGA 252,000 41 4.25% 1.88 1.880 234
Live vaccine 276,000 41 5.00% 1.89 1.875 231
Commercial broiler breeder hens (Ross and Cobb breeds) were vaccinated twice with purified gametocyte antigens (PGA) at 15 and 20 weeks of age. Eggs were
collected from groups of vaccinated and unvaccinated hens, incubated to hatching and broiler birds raised under normal commercial conditions for each country.
Control flocks were either immunized with a commercial live vaccine or raised on feed containing anticoccidial chemoprophylactic drugs. There was no significant
difference between the performance of control and vaccinated birds with respect to age at slaughter, mortality, Feed Conversion Rate (FCR), final body weight or
European (EU) Performance Index (one-way ANOVA).
*These farms were from large integrations, and the results are from several chicken houses run over a period of 2–3 years.
**The results from Israel are the summary from several different farms run over a period of 5 years.
doi:10.1371/journal.pone.0003948.t004
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Vaccine efficacy was tested by immunising Specific Pathogen Free
chickens with a given batch and demonstrating by ELISA that the
antibody titre induced was above the cut-off level required for
providing protective immunity (see below). These tests were
carried out at ABIC Ltd., Israel under the rules for animal ethics in
accordance with Israeli law and those of the Veterinary
Laboratory Agency, United Kingdom (the VLA is bound by the
Animals (Scientific Procedures) Act 1986, which is administered by
the Home Office, UK). Each 0.5 ml dose of vaccine contained
50 mg of gametocyte antigen. Hens were vaccinated twice by
intramuscular injection - at 15 and 20 weeks of age – that is, just
prior to the start of their laying period. All experiments were
monitored by qualified scientists, veterinarians and the farmers
themselves. Feed was provided by commercial companies that
were instructed to clean out the chutes used for preparing our
batch from any remaining anticoccidial drugs prior to preparation
of the drug-free feed used in the trial. In order to be absolutely
certain that no errors were made at the feed mill, the feed was
tested for the presence (in the case of feed used as a drug
containing control group) or absence (used for the vaccinated
group) of the coccidiostats being used at that time in that particular
feed mill. In the rare event there was an error made in preparing
the feed, the experiment was aborted.
Measurement of antibody levels
Sera were taken on the day of the first vaccination and then
commencing 4 weeks post immunization. Sera were collected
periodically until the end of the laying period and antibody levels
measured by ELISA. The ELISA kit was produced by ABIC Ltd,
Bet Shemesh, Israel, and was used exactly as recommended by the
manufacturers. The kit contains ELISA plates coated with affinity
purified macrogametocyte antigen from E. maxima, plus known
positive and negative control sera and all the reagents needed for
performing the test. The ELISA results are expressed as an S/P
ratio, which is calculated as follows: (Sample optical density value
– Negative control optical density value)/(Positive control optical
density value – Negative control optical density value). A cut-off S/
P value of 0.4 has been determined by the manufacturers to
indicate a sufficiently high antibody level to confer protective
maternal immunity against coccidiosis.
Oocyst counts
Faecal oocyst counts or litter oocyst counts from samples
collected weekly from individual chicken houses were performed
as described previously [16]. For litter counts, samples were
collected at a variety of points within the shed, the litter was well
mixed, a sample was weighed, water was added and left overnight
at 4uC. The sample was then mixed well, filtered through a
strainer, spun at 1500 rpm for 5 minutes and brought back to the
original volume with a saturated salt solution. Oocyst counting was
performed using a McMaster flotation chamber. The number of
oocysts per gram litter or faeces was calculated by dividing the
number of oocysts counted microscopically by 0.15, multiplying by
the dilution factor and then dividing by the weight in grams of the
sample.
Assessment of performance of chickens
For breeder farms, hens were kept in separate but very similar
houses, and monitored for mortality, morbidity, egg laying and
hatchability of chicks. Calculations were made as far as the
number of eggs laid per hen and the number of chicks hatched per
hen in the vaccinated versus control groups.
For the broiler chicks, houses were monitored for chicken
mortality, weight gain and feed conversion. The feed conversion
ratio (FCR) was calculated by Feed(kg)/BW(kg). The EU
performance index was calculated using the following formula:
(Body weight (kg)610,000)/(FCR6slaughter age in days). All of
the studies using commercial breeder and broiler chickens were
carried out in accordance with commercial growing and animal
experimentation rules governing their care & welfare in each of
the countries where tests were performed (Thailand, India, South
Africa, Israel, Argentina and Brazil).
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